Scholarlink

Background <p>Non-invasive screening of acute coronary syndromes (ACS) is a clinical challenge. Considering the significance of microRNAs (miRNAs), the significance of miR-629–5p in the onset and development of ACS was assessed, aiming to explore a novel biomarker.</p> Methods <p>This study compared serum miR-629–5p between 115 ACS patients and 103 chest pain cases. The significance of serum miR-629–5p in screening ACS onset, predicting risk, development, and outcomes was evaluated. Additionally, to reveal the regulatory mechanism underlying miR-629–5p, in vitro cellular evaluation was conducted with hypoxia/reoxygenation (H/R)-induced H9c2 cells. The effect of miR-629–5p on cell viability, inflammation, and oxidative stress was investigated.</p> Results <p>Decreasing serum miR-629–5p levels in ACS patients could predict the risk of disease onset, significantly discriminated ACS patients, and predicted adverse outcomes of ACS patients. miR-629–5p showed significant negative correlations with creatine kinase-MB (CK-MB) levels D-dimer (D-D), and Fibrinogen (Fig) levels in ACS patients. Significant negative correlation was also observed in the SYNTAX score and Gensini score. In H/R-induced myocardial cells, overexpressing miR-629–5p could alleviate cell injury, improving cell viability, attenuating inflammation, and oxidative stress. MMP16 was predicted as the downstream target of miR-629–5p, which showed contrast dysregulation in H/R-induced H9c2 cells and was negatively regulated by miR-629–5p. The overexpression of MMP16 could reverse the protective effect of miR-629–5p on H/R-induced myocardial cell injury.</p> Conclusion <p>miR-629–5p could be considered as a diagnostic and prognostic biomarker for ACS. miR-629–5p regulates myocardial cell injury by directly targeting MMP16, of great potential in serving as a therapeutic target for ACS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Significance of miR-629-5p in the prediction of acute coronary syndrome onset, severity, and development

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月21日

查看全文
  • Qingli Wang,
  • Shuo Wang,
  • Liping Zhu,
  • Nina Chen,
  • Zhe Wang,
  • Heng Jiang

摘要

Background

Non-invasive screening of acute coronary syndromes (ACS) is a clinical challenge. Considering the significance of microRNAs (miRNAs), the significance of miR-629–5p in the onset and development of ACS was assessed, aiming to explore a novel biomarker.

Methods

This study compared serum miR-629–5p between 115 ACS patients and 103 chest pain cases. The significance of serum miR-629–5p in screening ACS onset, predicting risk, development, and outcomes was evaluated. Additionally, to reveal the regulatory mechanism underlying miR-629–5p, in vitro cellular evaluation was conducted with hypoxia/reoxygenation (H/R)-induced H9c2 cells. The effect of miR-629–5p on cell viability, inflammation, and oxidative stress was investigated.

Results

Decreasing serum miR-629–5p levels in ACS patients could predict the risk of disease onset, significantly discriminated ACS patients, and predicted adverse outcomes of ACS patients. miR-629–5p showed significant negative correlations with creatine kinase-MB (CK-MB) levels D-dimer (D-D), and Fibrinogen (Fig) levels in ACS patients. Significant negative correlation was also observed in the SYNTAX score and Gensini score. In H/R-induced myocardial cells, overexpressing miR-629–5p could alleviate cell injury, improving cell viability, attenuating inflammation, and oxidative stress. MMP16 was predicted as the downstream target of miR-629–5p, which showed contrast dysregulation in H/R-induced H9c2 cells and was negatively regulated by miR-629–5p. The overexpression of MMP16 could reverse the protective effect of miR-629–5p on H/R-induced myocardial cell injury.

Conclusion

miR-629–5p could be considered as a diagnostic and prognostic biomarker for ACS. miR-629–5p regulates myocardial cell injury by directly targeting MMP16, of great potential in serving as a therapeutic target for ACS.